WINDLAS BIOTECH Q2 FY27 CONCALL: TARGETS FY28 TRADE GENERICS GROWTH RECOVERY, ₹25–30 CR COST-EFFICIENCY CAPEX; PLANT 6 ADDS ₹1,100 CR REVENUE CAPACITY, EU-GMP INJECTABLES CERTIFICATION SECURED & FURTHER MARGIN IMPROVEMENT EXPECTED